Business Wire

UAVITA-SYSTEMS

5.8.2021 22:00:11 CEST | Business Wire | Press release

Share
UAVita Systems Together With Nova Poshta Successfully Completed the World’s First Civilian Long Range Intercity Autonomous Drone Flight

On July 29, 2021, UAVita Systems made history with a world aviation industry first – autonomous drone delivery of commercial packages between two major cities.

The Nova poshta commercial flight of UAVita’s DISCOVERY D-80 drone between Kyiv and Kharkiv, two major cities in Ukraine, was 480 km between takeoff and landing and carried a load of five parcels for delivery. The flight was fully autonomous from takeoff to waypoint navigation to landing and crossed several rivers, highways, avoiding populated areas, infrastructure objects and restricted airspace.

Airspace for the flight was reserved with local air traffic control, state air services, and several military authorities. The flight was operated by UAVita’s local Ukraine company, Aerodrone.

"The flight went exactly as planned," said Yuri Pederiy, CTO of UAVita. "Nova poshta was very pleased with the results."

DISCOVERY’s average air speed was 100 kph, with an altitude of 300 meters and total flight time was 4:45 hours a full hour ahead of schedule due to a tail wind.

"Commercial UAV with packages over the distance of 480 km is first in the world," said Oleksandr Bulba, CEO of Nova poshta. "Beside Nova poshta there is no other logistic company that has completed this flight. Our plans are to shorten the flight time to 3 hours to cover the same distance and scale up package drone delivery and make it more affordable to our customers."

Nova poshta’s and UAVita’s next autonomous parcel delivery test flight will take place in late August between the cities of Kyiv and L’viv. The target is to eventually reduce the flight time even further by deploying UAVita’s next generation drones.

“Most conventional drone deliveries are focused on last mile delivery within few kilometers. UAVita took the leap and developed intercity package delivery. This capability adds more flexibility to shipping urgent and high value packages especially to remote locations that are difficult to reach by ground transportation. Combining last mile and intercity delivery can further automate the logistic chain and optimize the operating costs for the courier companies,” explained Pederiy.

Nova poshta is a private Ukrainian postal and courier company and the leader of the logistics in the Ukraine market that provides express delivery of documents, freight and parcels for individuals and businesses. The company delivers shipments through more than 8500 branches, 6700 lockers, and to the customer’s physical address. In 2020 Nova poshta delivered over 318 million shipments throughout Ukraine.

UAVita is a designer, manufacturer and integrator of purpose-built fixed wing high payload autonomous drones. UAVita’s DISCOVERY D-80 drone was recently awarded top place in the Krypto Labs Drone X Challenge 2020 . The DISCOVERY is an industry leading drone with a maximum payload of 80 kg and non-stop flight time of 10 hours or 1000 km. UAVita is set to launch their next generation fixed wing drone that has a maximum payload of 340 kg and non-stop flight time of 30 hours or 4500 km.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye